This article reviews the long-term safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder based on the SAkuraMoon extension trial.
The 50-year follow-up study on the Auckland Steroid Trial provides reassurance about the intergenerational safety of antenatal corticosteroid exposure concerning body mass index and various health outcomes in the second generation.